MVA Members

IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies. The company is focused on development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials. IO Biotech has achieved a proven track record of progressing pre-clinical and clinical compounds:

• Two lead anti-cancer therapies targeting IDO and PD-L1 are in clinical development
• Several compounds finalizing preclinical phase

IO Biotech is located in Copenhagen and was founded in December 2014 as a spin out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic products.